BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 17,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 17,000 shares of BioNTech stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00. Following the sale, the chief executive officer owned 197,209 shares in the company, valued at $19,219,989.14. The trade was a 7.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00.

BioNTech Stock Performance

NASDAQ BNTX traded up $0.05 during trading on Friday, hitting $96.90. 681,351 shares of the company’s stock traded hands, compared to its average volume of 1,087,641. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The stock has a market capitalization of $24.50 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The business has a 50 day moving average of $98.66 and a 200-day moving average of $94.99.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech’s revenue for the quarter was down 59.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.60) EPS. As a group, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Flossbach Von Storch SE bought a new stake in shares of BioNTech during the 2nd quarter worth $207,142,000. Bank of America Corp DE increased its stake in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares during the last quarter. First Trust Advisors LP increased its stake in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after acquiring an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in BioNTech during the second quarter valued at about $39,385,000. Finally, CenterBook Partners LP raised its position in BioNTech by 27.3% during the fourth quarter. CenterBook Partners LP now owns 236,175 shares of the company’s stock valued at $22,484,000 after purchasing an additional 50,684 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Morgan Stanley decreased their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th. Berenberg Bank set a $140.00 price objective on shares of BioNTech in a research note on Wednesday, September 16th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Citigroup cut their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group decreased their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.